Nike co-founder Phil Knight to donate $2 billion to OHSU’s Knight Cancer Institute

Nike co-founder Phil Knight to donate  billion to OHSU’s Knight Cancer Institute


Phil Knight

Matthew Staver | Bloomberg | Getty Images

Nike co-founder Phil Knight is donating $2 billion to the Oregon Health and Science University’s Knight Cancer Institute, the single largest donation ever to a U.S. university, college or health institution, according to the Knight Foundation.

The foundation said on Thursday the gift that will be used to shift the scientific approach to cancer treatment, research and patient care outcomes.

As part of the gift, the Knights will partner with cancer research pioneer Dr. Brian Druker.

A decade ago, Druker and OHSU took on a challenge to raise $500 million for cancer research, and the Knights signed on to match the raise dollar-for-dollar.

“We are grateful for the opportunity to invest in the next stage of the Druker-led revolutionary vision of cancer research, diagnosis, treatment, care, and some day, eradication,” Phil and Penny Knight said in a statement. “We couldn’t be more excited about the transformational potential of this work for humanity.”

Phil and Penny Knight with Dr. Brian Druker of the OHSU Knight Cancer Institute.

Courtesy of OHSU Knight Cancer Institute.

Knight’s fortune stems from his success with the swoosh, the company he founded in 1964.

Originally called Blue Ribbon Sports, the business began humbly, with Knight selling sneakers out of the trunk of his car, as he recounted in his 2016 memoir, “Shoe Dog.”

Get the CNBC Sport newsletter directly to your inbox

The CNBC Sport newsletter with Alex Sherman brings you the biggest news and exclusive interviews from the worlds of sports business and media, delivered weekly to your inbox.

Subscribe here to get access today.

Nike went public in December 1980 and quickly became the most dominant sneaker brand, partnered with some of the top athletes across sport.

During Knight’s tenure at the public company, from its IPO to his June 2016 retirement, Nike shares soared almost 30,500%.

Although Nike stock has had a painful few years, down more than 50% from its peak in late 2021, it remains the most valuable public company in athletic footwear, valued at more than $110 billion.

The Knights are regularly found on lists of top philanthropists. In May, Time Magazine estimated their lifetime giving at $3.6 billion, including $370 million gifted in 2024 alone.

According to the Knight Foundation’s latest tax documents the foundation held more than $5 billion in assets at the end of 2023.

“I wanted to build something that was my own, something I could point to and say: I made that. It was the only way I saw to make life meaningful,” Knight said in his 2016 memoir.

Correction: The headline on this story has been updated to correct that Phil Knight is donating to Oregon Health and Science University’s Knight Cancer Institute. A previous version misstated the institution.



Source

OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More
Thanks for your support, here’s how to connect with us
Health

Thanks for your support, here’s how to connect with us

When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the 30 million people living with them, we knew the response would be big. We didn’t know it would be this big. The response has been amazing, overwhelming and humbling. Thank you for your interest — […]

Read More
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More